-
1
-
-
0032447719
-
Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy
-
Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998;3:215-220.
-
(1998)
Antivir Ther
, vol.3
, pp. 215-220
-
-
Burger, D.M.1
Hoetelmans, R.M.2
Hugen, P.W.3
-
2
-
-
0035824741
-
Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals
-
Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001;15:2379-2384.
-
(2001)
AIDS
, vol.15
, pp. 2379-2384
-
-
Phillips, A.N.1
Miller, V.2
Sabin, C.3
-
3
-
-
0034319263
-
Prospective randomized two arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
-
Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-228.
-
(2000)
J Acquir Immune Defic Syndr
, vol.25
, pp. 221-228
-
-
Tuldra, A.1
Fumaz, C.R.2
Ferrer, M.J.3
-
4
-
-
0035902939
-
Simplification with abacavir based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
-
Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-1526.
-
(2001)
AIDS
, vol.15
, pp. 1517-1526
-
-
Clumeck, N.1
Goebel, F.2
Rozenbaum, W.3
-
5
-
-
0035876184
-
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals
-
Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15:1089-1095.
-
(2001)
AIDS
, vol.15
, pp. 1089-1095
-
-
Veldkamp, A.I.1
Weverling, G.J.2
Lange, J.M.3
-
6
-
-
0035198762
-
Principles and practice of HIV-protease inhibitor pharmacoenhancement
-
Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-113.
-
(2001)
HIV Med
, vol.2
, pp. 105-113
-
-
Moyle, G.J.1
Back, D.2
-
7
-
-
0033972441
-
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
-
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
-
(2000)
Clin Pharmacokinet
, vol.38
, pp. 41-57
-
-
Dresser, G.K.1
Spence, J.D.2
Bailey, D.G.3
-
8
-
-
0035461510
-
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration
-
Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001;52:255-264.
-
(2001)
Br J Clin Pharmacol
, vol.52
, pp. 255-264
-
-
Buss, N.1
Snell, P.2
Bock, J.3
Hsu, A.4
Jorga, K.5
-
9
-
-
0035477744
-
Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HERS study
-
Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HERS study. J Acquir Immune Defic Syndr 2001;28:124-131.
-
(2001)
J Acquir Immune Defic Syndr
, vol.28
, pp. 124-131
-
-
Stone, V.E.1
Hogan, J.W.2
Schuman, P.3
-
10
-
-
0035958773
-
Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults
-
Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001;15:1369-1377.
-
(2001)
AIDS
, vol.15
, pp. 1369-1377
-
-
Bartlett, J.A.1
DeMasi, R.2
Quinn, J.3
Moxham, C.4
Rousseau, F.5
-
11
-
-
0038078754
-
Reviving protease inhibitors: New data and more options
-
Murphy RL. Reviving protease inhibitors: new data and more options. J Acquir Immune Defic Syndr 2003;33:S43-52.
-
(2003)
J Acquir Immune Defic Syndr
, vol.33
-
-
Murphy, R.L.1
-
12
-
-
0347128503
-
Lipid abnormalities during ART: It's the drug, not the class
-
Moyle GJ. Lipid abnormalities during ART: It's the drug, not the class. AIDS Read 2004;14:15-22.
-
(2004)
AIDS Read
, vol.14
, pp. 15-22
-
-
Moyle, G.J.1
-
13
-
-
0041733063
-
-
Goldsmith DR, Perry CM. Atazanavir. Drugs 2003;63:1679-1693; discussion 1694-1695.
-
Goldsmith DR, Perry CM. Atazanavir. Drugs 2003;63:1679-1693; discussion 1694-1695.
-
-
-
-
14
-
-
2942527107
-
Atazanavir: New option for treatment of HIV infection
-
Havlir DV, O'Marro SD. Atazanavir: New option for treatment of HIV infection. Clin Infect Dis 2004;38:1599-1604.
-
(2004)
Clin Infect Dis
, vol.38
, pp. 1599-1604
-
-
Havlir, D.V.1
O'Marro, S.D.2
-
15
-
-
3342924014
-
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV
-
Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011-1019.
-
(2004)
J Acquir Immune Defic Syndr
, vol.36
, pp. 1011-1019
-
-
Squires, K.1
Lazzarin, A.2
Gatell, J.M.3
-
16
-
-
0037234238
-
Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects
-
Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18-29.
-
(2003)
J Acquir Immune Defic Syndr
, vol.32
, pp. 18-29
-
-
Sanne, I.1
Piliero, P.2
Squires, K.3
Thiry, A.4
Schnittman, S.5
-
17
-
-
1642465026
-
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results
-
Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003;17:2603-2614.
-
(2003)
AIDS
, vol.17
, pp. 2603-2614
-
-
Murphy, R.L.1
Sanne, I.2
Cahn, P.3
-
18
-
-
2542489421
-
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir
-
Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004;36:684-692.
-
(2004)
J Acquir Immune Defic Syndr
, vol.36
, pp. 684-692
-
-
Wood, R.1
Phanuphak, P.2
Cahn, P.3
-
19
-
-
33747126527
-
Efficacy and safety of atazanavir (ATV)-based HAART in patients switched from a stable boosted or unboosted protease inhibitor (PI) treatment. The SWAN Study: Final Results (48 Weeks)
-
Dublin: November
-
Gatell JM, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV)-based HAART in patients switched from a stable boosted or unboosted protease inhibitor (PI) treatment. The SWAN Study: Final Results (48 Weeks). 10th European AIDS Conference. Dublin: November 2005.
-
(2005)
10th European AIDS Conference
-
-
Gatell, J.M.1
Salmon-Ceron, D.2
Lazzarin, A.3
-
20
-
-
70349451266
-
Open-label, pilot trial of regimen simplification to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression (ACTG 5201)
-
Denver: February
-
Swindells S, Wilkin T, DiRienzo G, et al. Open-label, pilot trial of regimen simplification to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression (ACTG 5201). 13th Conference on Retroviruses and Opportunistic Infections. Denver: February 2006.
-
(2006)
13th Conference on Retroviruses and Opportunistic Infections
-
-
Swindells, S.1
Wilkin, T.2
DiRienzo, G.3
-
21
-
-
33747141841
-
Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48 week results from AI424-089
-
abstract 107LB, Denver: February
-
Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48 week results from AI424-089 [abstract 107LB]. 13th Conference on Retroviruses and Opportunistic Infections. Denver: February 2006.
-
(2006)
13th Conference on Retroviruses and Opportunistic Infections
-
-
Malan, N.1
Krantz, E.2
David, N.3
-
22
-
-
27144482749
-
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial
-
Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial. Curr Med Res Opin 2005;21:1683-1692.
-
(2005)
Curr Med Res Opin
, vol.21
, pp. 1683-1692
-
-
Cohen, C.1
Nieto-Cisneros, L.2
Zala, C.3
-
23
-
-
17844387166
-
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
-
Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-694.
-
(2005)
AIDS
, vol.19
, pp. 685-694
-
-
Johnson, M.1
Grinsztejn, B.2
Rodriguez, C.3
-
24
-
-
33646744190
-
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
-
Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718.
-
(2006)
AIDS
, vol.20
, pp. 711-718
-
-
Johnson, M.1
Grinsztejn, B.2
Rodriguez, C.3
-
25
-
-
33750999624
-
on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
-
Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006;7:487-503.
-
(2006)
HIV Med
, vol.7
, pp. 487-503
-
-
Gazzard, B.1
-
27
-
-
7944228403
-
Predictors of virological response to atazanavir in protease inhibitor-experienced patients
-
Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004;5:201-205.
-
(2004)
HIV Clin Trials
, vol.5
, pp. 201-205
-
-
Barrios, A.1
Rendon, A.L.2
Gallego, O.3
-
28
-
-
33846460075
-
Different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patients [Abstract 89]. XV International HIV Drug Resistance Workshop. Sitges: June 2006
-
Bertoli A, Santoro MM, Lorenzini P, et al. Different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patients [Abstract 89]. XV International HIV Drug Resistance Workshop. Sitges: June 2006. Antivir Ther 2006;11:S99.
-
(2006)
Antivir Ther
, vol.11
-
-
Bertoli, A.1
Santoro, M.M.2
Lorenzini, P.3
|